Petvivo Holdings SEC Filings

Costantino Robert J reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. reported that director Robert J. Costantino received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service. The grant, valued at $0.74 per share for reporting purposes, increases his direct holdings to 108,661 shares of common stock.

PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.

The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.

PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.

The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.

LOWENTHAL GARRY N reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. granted 71,993 shares of restricted common stock at $0.69 per share to a corporation owned by Chief Financial Officer Garry N. Lowenthal as compensation for past performance. These shares are held indirectly, bringing his reported indirect holdings to 812,460 shares.

LOWENTHAL GARRY N reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. granted 71,993 shares of restricted common stock at $0.69 per share to a corporation owned by Chief Financial Officer Garry N. Lowenthal as compensation for past performance. These shares are held indirectly, bringing his reported indirect holdings to 812,460 shares.

PetVivo Holdings, Inc. reported that Chief Executive Officer John Lai indirectly acquired 72,282 shares of restricted common stock. The shares were granted to a corporation he owns as compensation for his past performance. Following this award, that corporation’s indirect holdings increased to 2,240,492 common shares.

PetVivo Holdings, Inc. reported that Chief Executive Officer John Lai indirectly acquired 72,282 shares of restricted common stock. The shares were granted to a corporation he owns as compensation for his past performance. Following this award, that corporation’s indirect holdings increased to 2,240,492 common shares.

PetVivo Holdings, Inc. reported another loss-making quarter for the period ended December 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern. Quarterly revenue fell to $286,108 from $583,313 a year earlier, while the net loss available to common stockholders widened to $2,316,455. For the nine months, revenue was $886,892 versus $907,783, with a net loss of $7,788,904. Cash dropped to just $18,164, against an accumulated deficit of $98,987,394. The company shifted away from prior distributors, now relying heavily on Vedco for most sales, and added new licensing agreements for PrecisePRP and an AI platform that it expects to drive future revenue.

PetVivo Holdings, Inc. reported another loss-making quarter for the period ended December 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern. Quarterly revenue fell to $286,108 from $583,313 a year earlier, while the net loss available to common stockholders widened to $2,316,455. For the nine months, revenue was $886,892 versus $907,783, with a net loss of $7,788,904. Cash dropped to just $18,164, against an accumulated deficit of $98,987,394. The company shifted away from prior distributors, now relying heavily on Vedco for most sales, and added new licensing agreements for PrecisePRP and an AI platform that it expects to drive future revenue.

PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.

Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.

PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.

Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.

PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.

The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.

PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.

The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.

PetVivo Holdings, Inc. investor updates ownership report. Individual shareholder Stanley Cruden reports beneficial ownership of 3,620,163 shares of PetVivo common stock, representing 9.37% of the class, as of the event date of 12/31/2025. He has sole power to vote and dispose of all these shares and reports no shared voting or dispositive power.

The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PetVivo Holdings, Inc., nor in connection with any control-related transaction, other than activities solely in connection with a nomination under the cited proxy rule.

PetVivo Holdings, Inc. investor updates ownership report. Individual shareholder Stanley Cruden reports beneficial ownership of 3,620,163 shares of PetVivo common stock, representing 9.37% of the class, as of the event date of 12/31/2025. He has sole power to vote and dispose of all these shares and reports no shared voting or dispositive power.

The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PetVivo Holdings, Inc., nor in connection with any control-related transaction, other than activities solely in connection with a nomination under the cited proxy rule.

PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.

PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.

PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.

Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).

The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.

PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.

Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).

The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.